KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy

Frank Kullmann(Klinikum Weiden), Esther Endlicher(University Hospital Regensburg), Andreas Kutscheidt(Asklepios Klinik Langen), Helmut Messmann(University Hospital Augsburg), Arndt Hartmann(Universitätsklinikum Erlangen), Matthias Dollinger(University Hospital in Halle), Jörg Trojan(Goethe University Frankfurt), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), S. Hollerbach(Universitätsklinikum Knappschaftskrankenhaus Bochum), Martin Fuchs(München Klinik Bogenhausen), Jan Harder(Hegau-Bodensee-Klinikum Singen), M. Troppmann(University of Regensburg)
Oncology
January 1, 2011
10.1159/000330194
Cited by 46

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|660
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550